Logo image of EFTR

EFFECTOR THERAPEUTICS INC (EFTR) Stock Fundamental Analysis

NASDAQ:EFTR - Nasdaq - US28202V2079 - Common Stock - Currency: USD

0.18  -0.09 (-32.56%)

After market: 0.155 -0.02 (-13.89%)

Fundamental Rating

2

Taking everything into account, EFTR scores 2 out of 10 in our fundamental rating. EFTR was compared to 568 industry peers in the Biotechnology industry. While EFTR seems to be doing ok healthwise, there are quite some concerns on its profitability. EFTR is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year EFTR has reported negative net income.
EFTR had a negative operating cash flow in the past year.
In multiple years EFTR reported negative net income over the last 5 years.
EFTR had negative operating cash flow in 4 of the past 5 years.
EFTR Yearly Net Income VS EBIT VS OCF VS FCFEFTR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 0 10M -10M -20M -30M

1.2 Ratios

EFTR's Return On Assets of -127.64% is on the low side compared to the rest of the industry. EFTR is outperformed by 83.39% of its industry peers.
EFTR has a worse Return On Equity (-4187.55%) than 84.27% of its industry peers.
Industry RankSector Rank
ROA -127.64%
ROE -4187.55%
ROIC N/A
ROA(3y)-74.35%
ROA(5y)-100.19%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
EFTR Yearly ROA, ROE, ROICEFTR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 0 200 -200 400 -400 600 -600

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for EFTR so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
EFTR Yearly Profit, Operating, Gross MarginsEFTR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 0 1K -1K -2K

More info and screens

4

2. Health

2.1 Basic Checks

EFTR does not have a ROIC to compare to the WACC, probably because it is not profitable.
EFTR has more shares outstanding than it did 1 year ago.
The debt/assets ratio for EFTR is higher compared to a year ago.
EFTR Yearly Shares OutstandingEFTR Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 500K 1M 1.5M 2M 2.5M
EFTR Yearly Total Debt VS Total AssetsEFTR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M

2.2 Solvency

EFTR has an Altman-Z score of -13.64. This is a bad value and indicates that EFTR is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -13.64, EFTR is not doing good in the industry: 83.57% of the companies in the same industry are doing better.
There is no outstanding debt for EFTR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -13.64
ROIC/WACCN/A
WACC7.97%
EFTR Yearly LT Debt VS Equity VS FCFEFTR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 0 10M -10M -20M

2.3 Liquidity

A Current Ratio of 1.03 indicates that EFTR should not have too much problems paying its short term obligations.
EFTR has a worse Current ratio (1.03) than 88.46% of its industry peers.
EFTR has a Quick Ratio of 1.03. This is a normal value and indicates that EFTR is financially healthy and should not expect problems in meeting its short term obligations.
With a Quick ratio value of 1.03, EFTR is not doing good in the industry: 86.89% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.03
Quick Ratio 1.03
EFTR Yearly Current Assets VS Current LiabilitesEFTR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M

More info and screens

1

3. Growth

3.1 Past

EFTR shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -9.92%.
Looking at the last year, EFTR shows a very negative growth in Revenue. The Revenue has decreased by -100.00% in the last year.
EPS 1Y (TTM)-9.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%64%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

EFTR is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 14.92% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y66.09%
EPS Next 2Y36.54%
EPS Next 3Y24.92%
EPS Next 5Y14.92%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EFTR Yearly Revenue VS EstimatesEFTR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2027 2028 2029 2030 100M 200M 300M 400M
EFTR Yearly EPS VS EstimatesEFTR Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -5 -10 -15

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for EFTR. In the last year negative earnings were reported.
Also next year EFTR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
EFTR Price Earnings VS Forward Price EarningsEFTR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
EFTR Per share dataEFTR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4 -6 -8 -10

4.3 Compensation for Growth

A more expensive valuation may be justified as EFTR's earnings are expected to grow with 24.92% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.54%
EPS Next 3Y24.92%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for EFTR!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

EFFECTOR THERAPEUTICS INC

NASDAQ:EFTR (7/2/2024, 8:16:09 PM)

After market: 0.155 -0.02 (-13.89%)

0.18

-0.09 (-32.56%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-09 2024-05-09/amc
Earnings (Next)08-06 2024-08-06/amc
Inst Owners5.71%
Inst Owner Change0%
Ins Owners89.77%
Ins Owner Change0%
Market Cap846.00K
Analysts85
Price Target11.22 (6133.33%)
Short Float %0.13%
Short Ratio0.01
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-50.51%
Min EPS beat(2)-103.21%
Max EPS beat(2)2.19%
EPS beat(4)2
Avg EPS beat(4)-22.16%
Min EPS beat(4)-103.21%
Max EPS beat(4)15.72%
EPS beat(8)3
Avg EPS beat(8)-20.14%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-51.11%
EPS NQ rev (1m)-16.43%
EPS NQ rev (3m)-20.6%
EPS NY rev (1m)0%
EPS NY rev (3m)-8.7%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.02
P/tB 1.02
EV/EBITDA N/A
EPS(TTM)-13.08
EYN/A
EPS(NY)-2.29
Fwd EYN/A
FCF(TTM)-6.23
FCFYN/A
OCF(TTM)-6.21
OCFYN/A
SpS0
BVpS0.18
TBVpS0.18
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -127.64%
ROE -4187.55%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-74.35%
ROA(5y)-100.19%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 75.68%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.03
Quick Ratio 1.03
Altman-Z -13.64
F-Score4
WACC7.97%
ROIC/WACCN/A
Cap/Depr(3y)208.22%
Cap/Depr(5y)144.44%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-9.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%64%
EPS Next Y66.09%
EPS Next 2Y36.54%
EPS Next 3Y24.92%
EPS Next 5Y14.92%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y7.59%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-102.29%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-10.53%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-10.62%
OCF growth 3YN/A
OCF growth 5YN/A